Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

King Expects Settlements With SEC and OIG Will Not Exceed $130 Mil.

This article was originally published in The Pink Sheet Daily

Executive Summary

King anticipates that the cost of settling Medicaid underpayment investigations will not exceed the $130 mil. already set aside

You may also be interested in...



King Keeps Medicaid Business, Gives Up $124 Mil. Under Rebate Settlement

The "relator" could object to the settlements, which might prevent consummation of agreements with states and the federal government.

King Keeps Medicaid Business, Gives Up $124 Mil. Under Rebate Settlement

The "relator" could object to the settlements, which might prevent consummation of agreements with states and the federal government.

King's Review Of Product Returns Could Scuttle Mylan Merger

Both companies say the issues stem from historical practices and will not affect King's business going forward. Mylan says it remains committed to acquiring King but seeks further quantification of any financial restatement relating to King's recognition of product returns.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS057972

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel